Drug intelligence / Profile preview

INT-2108

Development stage: Unknown
Lead developer: Interius Biotherapeutics
Modality: Small Molecules, Cell Therapies, Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intravenous

Overview

INT-2108 is an off-the-shelf, lentivector-based chimeric antigen receptor (CAR) therapeutic candidate in preclinical development by Interius BioTherapeutics. It is designed as an in vivo CAR therapy, meaning the lentivector delivers genetic instructions directly to T and NK cells within the patient’s body to generate CAR T and CAR NK cells without ex vivo cell manipulation. The specific target(s), mechanism of action, and primary disease indication for INT-2108 have not been publicly disclosed as of April 2025. The drug remains at the discovery stage with no clinical trial data available[1][2].

Beyond the preview

Go deeper on INT-2108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INT-2108.

Explore the full profile